Free tool
FAERS Monitor: Clotic
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217628 or its brand name (Clotic, Clotrimazole). Reports on generic versions are filed under their own applications.
Reports
11,719
Serious
9,076
77% of reports
Hospitalization
4,025
Death reported
937
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,384
- nausea825
- macular degeneration812
- pain782
- off label use769
- headache754
- dyspnoea726
- fatigue660
- diarrhoea618
- pyrexia528
- malaise483
- rash478
- anxiety470
- weight decreased465
- condition aggravated445
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 84 |
| 2005 | 114 |
| 2006 | 135 |
| 2007 | 113 |
| 2008 | 122 |
| 2009 | 149 |
| 2010 | 169 |
| 2011 | 229 |
| 2012 | 342 |
| 2013 | 215 |
| 2014 | 296 |
| 2015 | 452 |
| 2016 | 629 |
| 2017 | 588 |
| 2018 | 786 |
| 2019 | 961 |
| 2020 | 863 |
| 2021 | 993 |
| 2022 | 931 |
| 2023 | 893 |
| 2024 | 1,008 |
| 2025 | 1,037 |
| 2026 | 609 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,440 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| macular degenerationSignal | 812 | 130.8 | 122.1 | 97,448 |
| weight decreasedSignal | 465 | 3.0 | 2.7 | 622 |
| anxietySignal | 470 | 3.0 | 2.7 | 618 |
| pyrexiaSignal | 528 | 2.7 | 2.5 | 591 |
| condition aggravatedSignal | 445 | 2.6 | 2.4 | 454 |
| dyspnoeaSignal | 726 | 2.3 | 2.1 | 548 |
| painSignal | 782 | 2.3 | 2.1 | 581 |
| headacheSignal | 754 | 2.2 | 2.0 | 482 |
| malaise | 483 | 2.0 | 1.8 | 237 |
| rash | 478 | 2.0 | 1.8 | 232 |
| drug ineffective | 1,384 | 1.9 | 1.8 | 613 |
| nausea | 825 | 1.9 | 1.8 | 347 |
| diarrhoea | 618 | 1.7 | 1.6 | 191 |
| off label use | 769 | 1.6 | 1.5 | 169 |
| fatigue | 660 | 1.5 | 1.4 | 122 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.